WO2004108178A1

WO2004108178A1 - Bone graft substitute composition

Info

Publication number: WO2004108178A1
Application number: PCT/US2004/015957
Authority: WO
Inventors: Leasa C. Miller; Kelly Coupe Richelsoph; Jon P. Moseley
Original assignee: Wright Medical Technology, Inc.
Priority date: 2003-05-30
Filing date: 2004-05-21
Publication date: 2004-12-16
Also published as: US20080031917A1; US7658768B2; US20030235621A1; US7291179B2

Abstract

Bone graft substitute compositions and methods of making the compositions are disclosed. In some embodiments, a method of making a composition includes contacting a mixing solution with a first mixture having calcium sulfate hernihydrate and a plasticizing material to form a second mixture; waiting a predetermined period of time after forming said second mixture; and then contacting dernineralized bone with the second mixture to form the composition. A composition can be formed from a kit including a first mixture having calcium sulfate hemihydrate and a plasticizing substance, a second mixture having dernineralized bone, and a mixing solution. The first and second mixtures and the mixing solution are unblended.

Description

BONE GRAFT SUBSTITUTE COMPOSITION

TECHNICAL FIELD The invention relates to bone graft substitute compositions.

BACKGROUND

Compositions containing calcium sulfate can be used as filler for voids and/or defects defined by bone, h some embodiments, the compositions can promote bone growth.

SUMMARY

In one aspect, the invention relates to bone graft substitute compositions. In another aspect, the invention features a method of making a composition. The method includes contacting a mixing solution with a first mixture having calcium sulfate hernihydrate and a plasticizing material to form a second mixture; and after waiting a predetermined time, contacting dernineralized bone with the second mixture to form the composition. hi another aspect, the invention features a kit, including a first mixture having calcium sulfate hernihydrate and a plasticizing substance, a second mixture having dernineralized bone, the second mixture being unblended with the first mixture, and a mixing solution unblended with the first and second mixtures. The kit can include instructions for making a bone graft composition as described herein.

The first mixture can further include a first material capable of accelerating formation of calcium sulfate dihydrate from the calcium sulfate hernihydrate, such as calcium sulfate dihydrate coated with sucrose. Other aspects, features, and advantages of the invention will be apparent from the description of the preferred embodiments thereof and from the claims. DETAILED DESCRIPTION Bone graft substitute compositions including surgical-grade calcium sulfate hernihydrate (CaSO₄ ^-12H₂O); dernineralized bone matrix; a material that accelerates hardening of the composition ("an accelerant"); a plasticizing material; and a mixing solution are described in Applicants' co-pending US Serial Number 10/179,533. Furthermore, bone graft compositions including surgical-grade calcium sulfate hernihydrate (CaSO ^-1/2H O); dernineralized bone matrix; a plasticizing material; and a mixing solution are also described in Applicants' co-pending US Serial Number 10/060,697 (and other members of that family). These compositions are prepared by mixing all the dry materials together simultaneously, and then combining the dry materials with the mixing solution.

Here, Applicants have found that during use, if the components are mixed together in a predetermined order and timing, consistent results, such as repeatable set times, are much more likely to be obtained. Applicants have found that the order and timing involves first forming a first mixture including the calcium sulfate, the plasticizing material, and the optional accelerant in a container. The mixing solution is then added to the container. The first mixture and the solution are mixed until blended, e.g., for about thirty seconds, and allowed to sit, e.g., for about another thirty seconds. During the initial one minute, the blend of the first mixture and mixing solution can be mixed the entire time or only a portion of the time (e.g., mixing and sitting).

After a total of about one minute, the dernineralized bone is then added to the blend and mixed thoroughly to form the composition. The composition can be delivered to a target site (e.g., a void or a defect) by injecting the composition through a syringe, and/or by forming (e.g., molding) a paste or a putty of the composition and applying the composition by hand (e.g., using fingers). After about 5-10 minutes, the composition can harden ex vivo or in vivo, e.g., to a hardness sufficient to support orthopedic hardware.

Without wishing to be bound by theory, it is believed that during use, e.g., after mixing the mixture of powders with the mixing solution, the calcium sulfate hernihydrate is converted, e.g., changes crystalline form, into calcium sulfate dihydrate (CaSO₄-2H₂O), which hardens the composition. Calcium sulfate dihydrate is capable of being sorbed by the body. It is believed that the method described above of making the composition allows the calcium sulfate hernihydrate to begin converting to calcium sulfate dihydrate before other ingredients of the composition, such as proteins from the dernineralized bone, interfere (e.g., stop) the conversion, hi any event, beneficial results have been found by waiting a predetermined period of time before adding the dernineralized bone to the second mixture. This method is different from, for example, U.S. Pat. No. 5,385,887 to Yim, in which calcium sulfate is added directly to a blood-BMP mixture.

For purposes of describing the concentrations of materials in the bone graft substitute composition, the composition includes 100 parts of calcium sulfate, e.g., calcium sulfate hernihydrate. Methods of making a calcium sulfate hernihydrate are described in U.S. Patent Nos. 5,614,206, 5,807,567, and 6,030,636, each of which is hereby incorporated by reference in its entirety.

The dernineralized bone matrix is believed to enhance bone growth. In some embodiments, the dernineralized bone matrix is freeze-dried to less than about 6% moisture. The dernineralized bone matrix can have a particle size of about 125-850 microns, e.g., about 125-710 microns. The particle size can be greater than or equal to about 125, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or 800 microns; and/or less than or equal to about 850, 800, 750, 700, 650, 600, 550, 500, 450, 400, 350, 300, 250, 200, or 150 microns. The calcium content in the dernineralized bone matrix can be about less than eight (8) percent. Dernineralized bone matrix is available, e.g., from Allosource (Denver, CO) or DCI (Nashville, TN).

For 100 parts of calcium sulfate (e.g., (CaSO₄ H₂O), the composition includes between about 10 and about 30 parts of dernineralized bone matrix, such as between about 15 and about 25 parts, or between about 19 and about 21 parts, or about 20 parts. In embodiments, the composition may include greater than or equal to about 10, 12, 14, 16, 18, 20, 22, 24, 26, or 28 parts of dernineralized bone matrix; and/or less than or equal to about 30, 28, 26, 24, 22, 20, 18, 16, 14, or 12 parts of dernineralized bone matrix. As described in Applicant's co-pending US Serial Number 10/179,533 and without wishing to be bound by theory, the accelerant is believed to enhance, e.g., accelerate, the conversion of calcium sulfate hernihydrate to calcium sulfate dihydrate. In particular, it is believed that particles of the accelerant act as crystallization nucleation sites for the conversion of calcium sulfate hernihydrate to calcium sulfate dihydrate. Examples of accelerants include calcium sulfate dihydrate, potassium sulfate, or sodium sulfate. Other examples include ionic salts. A preferred accelerant is calcium sulfate dihydrate crystals (available from U.S. Gypsum) coated with sucrose (available from VWR Scientific Products). A process of stabilizing the dihydrate crystals by coating with sucrose is described in U.S. Patent No. 3,573, 947, hereby incorporated by reference in its entirety.

For 100 parts of calcium sulfate (e.g., CaSO ^azH₂O), the composition includes between about 0.5 and about 5 parts of the accelerant, such as about 4.8 parts, or between about 1 and about 4 parts, or between about 2.5 and about 3.5 parts, or about 3 parts. The composition may include greater than or equal to about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 4.5 parts of the accelerant; and/or less than or equal to about 5, 4.5, 4, 3.5, 3, 2.5, 2, 1.5, or 1 parts of the accelerant. Mixtures of two or more accelerants can be used.

The plasticizing material is believed to provide the bone graft substitute composition with a consistency that helps the composition to form into a paste or putty, or to flow, e.g., to be injectable. Examples of plasticizing materials include cellulose derivatives, such as sodium carboxymethylcellulose, methylcellulose (MC), hydroxymethylcellulose, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), ethylcellulose (EC), hydroxyethylcellulose or cellulose acetate butyrate. Other examples of plasticizing material include high molecular weight alcohols including glycerol and vinyl alcohols, stearic acid, and hyaluronic acid. For 100 parts of calcium sulfate (e.g., CaSO₄'Vι>H₂O), the composition includes between about 0.5 and about 5 parts of the plasticizing material, such as between about 1 and about 3 parts, or between about 1.5 and about 2.5 parts, or about 2 parts. The composition may include greater than or equal to about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 4.5 parts of the plasticizing material; and/or less than or equal to about 5, 4.5, 4, 3.5, 3, 2.5, 2, 1.5, or 1 parts of the plasticizing material. Mixtures of two or more plasticizing materials can be used. The mixing solution is generally selected to provide the composition with a desired consistency and hardening time. Examples of a mixing solution include water, e.g., sterile water, solutions containing inorganic salts, or cationic surface active agents including sodium chloride, saline, e.g., phosphate buffered saline, potassium chloride, sodium sulfate, potassium sulfate, EDTA, ammonium sulfate, ammonium acetate, and sodium acetate. A specific example of a mixing solution is 0.9% NaCl saline solution (available from Baxter).

The concentration of mixing solution in the substitute composition varies and can be a function of, for example, the source (e.g., tissue bank) of the dernineralized bone matrix, and/or the desired consistency of the composition. Also, the amount of mixing solution added to the mixture of powders can affect the time the composition takes to set, i.e., the set time. Increasing the amount of mixing solution can increase the set time, and decreasing the amount of mixing solution added to the mixture of powders can reduce the set time. For example, for a putty comprising HPMC, 2.6 grams of water provided a set time of about 10-15 minutes, while 4.0 grams of water provided a set time of about 60 minutes.

In some embodiments, for 100 parts of calcium sulfate (e.g., (CaSOA J _^O), the composition includes between about 40 and about 60 parts of the mixing solution, such as between about 45 and about 55 parts, or between about 49 and about 51 parts, or about 50 parts. The composition may include greater than or equal to about 40, 45, 50, or 55 parts of the mixing solution; and/or less than or equal to about 60, 55, 50, or 45 parts of the mixing solution. Mixtures of two or more mixing solutions can be used.

The mixing solution can further include one or more additives such as, for example, bone marrow aspirate, platelet concentrate, blood, pharmaceutical additives in solution, or combinations of these materials. Other examples of additives include medicaments or pesticides. Examples of medicaments are antibiotics, chemotherapeutic agents, growth factors, and analgesics. Examples of antibiotics are tetracycline hydrochlori.de, vancomycin, cephalosporins, and aminoglycocides such as tobramycin and gentamicin. Examples of chemotherapeutic agents are cis-platinum, ifosfamide, ethotrexate, and doxorubicin hydrochloride (Adriamycin®). Examples of growth factors are transforming growth factor beta (TGF-Beta), bone morphogenic protein (BMP), basic fibroblast growth factor, platelet-derived growth factor, and other polypeptide growth factors. Examples of analgesics are anesthetics such as lidocaine hydrochloride (Xylocaine©), bipivacaine hydrochloride (Marcaine®), and non-steroidal anti-inflammatory drugs such as ketorolac tromethamine (Toradol®). Certain mixing solution and/or additives can affect, e.g., delay, the hardening properties of the composition. The additive(s) can be added to the composition after the dernineralized bone matrix has been added.

The composition as formed can be a conforming material having a paste-like or putty-like consistency, e.g., like Plaster of Paris, which can be applied digitally. The composition can be injected into a target site, for example, to fill into cracks or voids, some embodiments, the composition is capable of setting to a hardness, e.g., about 4.3 MPa, in about 5-15 minutes, e.g., greater than 5, 7, 9, 11, or 13 minutes, and/or less than 15, 13, 11, 9, or 7 minutes.

The hardened composition can be used for intra-operative support of hardware, such as orthopedic hardware, e.g., bone plates, distal radius hardware, and hardware used for tibial plateau fractures.

The following example is illustrative and not intended to be limiting.

Example A mixture of surgical-grade calcium sulfate hernihydrate (SGCSH) and hydroxypropylmethylcellulose (5.0 g total, 4.9 g hernihydrate with 0.1 g HPMC) was mixed and bottled, h a separate bottle, 0.96 g DBM was packaged. In a third vial, 2.38 g water was packaged. All three bottles were electron beam sterilized at 18 - 26 kGy. To mix the putty, the SGCSH blend was emptied into a bowl and the water was added. The powder was mixed for approximately 30 seconds and then allowed to rest for 30 seconds. After one minute had passed since the water had been added to the hernihydrate powder, the DBM was added to the calcium sulfate mixture and mixed thoroughly for approximately 30 seconds. A putty-like material was formed, setting in approximately 7 minutes. The strength of the hardened putty was approximately 4 MPa. Other Embodiments In some embodiments, the composition further includes a bioactive agent. Examples of bioactive agents include growth factors, hyaluronic acid, bone morphogenic proteins, bone autograft, bone marrow, etc. The composition may include sodium bicarbonate. For example, the composition may include 0.1-2% sodium bicarbonate by weight to provide a porous structure in the resultant composition.

Alternatively or in addition, the bone graft substitute composition may include one or more additive such as an antiviral agent, an antimicrobial agent, an antibiotic agent, an amino acid, a peptide, a vitamin, an inorganic element, a protein synthesis co-factor, a hormone, an endocrine tissue, a synthesizer, an enzyme, a polymer cell scaffolding agent with parenchymal cells, an angiogenic drug, a collagen lattice, an antigenic agent, a cytoskeletal agent, mesenchymal stem cells, a bone digester, an antitumor agent, a cellular attractant, fibronectin, a growth hormone, a cellular attachment agent, an immunosuppressant, a nucleic acid, a surface active agent, synthetically derived or naturally derived chips of minerals such as calcium phosphate, e.g., hydroxyapatite or tricalcium phosphate, or calcium carbonate, a penetration enhancer, allografts, e.g., a bone allo graft, cancellous bone chips (an osteoconductive substrate), and chunks, shards, and/or pellets of calcium sulfate. A number of embodiments of the invention have been described.

Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention.

Claims

WHAT IS CLAIMED IS:

1. A method of making a composition, comprising: contacting a mixing solution with a first mixture comprising calcium sulfate hernihydrate and a plasticizing material to form a second mixture; waiting a predetermined period of time after forming said second mixture; and then contacting dernineralized bone with the second mixture to form the composition.

2. The method of claim 1 , wherein said predetermined period of time is at least about thirty seconds after the second mixture is formed.

3. The method of claim 1 , wherein said predetermined period of time is at least about one minute after the second mixture is formed.

4. The method of claim 1 , wherein the first mixture further comprises a first material that accelerates formation of calcium sulfate dihydrate from the calcium sulfate hernihydrate.

5. The method of claim 4, wherein the first material comprises calcium sulfate dihydrate.

6. The method of claim 5, wherein the calcium sulfate dihydrate is coated with sucrose.

7. The method of claim 1 , wherein the plasticizing material is selected from the group consisting of cellulose derivatives, glycerol, vinyl alcohols, stearic acid, and hyaluronic acid.

8. The method of claim 1 , wherein the plasticizing material is a cellulose derivative selected from the group consisting of sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, and cellulose acetate butyrate.

9. The method of claim 1, wherein the plasticizing material comprises hydroxypropylmethylcellulose.

10. The method of claim 1, wherein the calcium sulfate hernihydrate is surgical grade.

11. The method of claim 1 , wherein the mixing solution comprises sterile water.

12. The method of claim 1 , wherein the composition comprises: 100 parts of calcium sulfate hernihydrate; about 0.5 to about 5 parts of the plasticizing material; and about 10 to about 30 parts of dernineralized bone.

13. The method of claim 1 , wherein the composition comprises: 100 parts of calcium sulfate hernihydrate; about 1 to about 3 parts of the plasticizing material; and about 15 to about 25 parts of dernineralized bone.

14. The method of claim 1 , wherein the calcium sulfate hernihydrate is surgical grade, the plasticizing material comprises hydroxypropylmethylcellulose, the mixing solution comprises sterile water, and wherein the composition further comprises calcium sulfate dihydrate.

15. The method of claim 14, wherein the composition comprises : 100 parts of calcium sulfate hernihydrate; about 0.5 to about 5 parts of calcium sulfate dihydrate; about 0.5 to about 5 parts of hydroxypropylmethylcellulose; and about 10 to about 30 parts of dernineralized bone.

16. The method of claim 14, wherein the composition comprises 100 parts of calcium sulfate hernihydrate; about 3 to about 5 parts of calcium sulfate dihydrate; about 1 to about 3 parts of hydroxypropylmethylcellulose; and about 15 to about 25 parts of dernineralized bone.

17. The method of claim 14, wherein said predetermined period of time is at least about thirty seconds after the second mixture is formed.

18. The method of claim 14, wherein the dernineralized bone is contacted with the second mixture at least about one minute after the second mixture is formed.

19. A kit, comprising: a first mixture comprising calcium sulfate hernihydrate and a plasticizing material; a second mixture comprising dernineralized bone, the second mixture being unblended with the first mixture; and a mixing solution unblended with the first and second mixtures.

20. The kit of claim 19, wherein the first mixture further comprises a first material capable of accelerating formation of calcium sulfate dihydrate from the calcium sulfate hernihydrate.

21. The kit of claim 20, wherein the first material comprises calcium sulfate dihydrate.

22. The kit of claim 21 , wherein the calcium sulfate dihydrate is coated with sucrose.

23. The kit of claim 19, wherein the plasticizing material is selected from the group consisting of cellulose derivatives, glycerol, vinyl alcohols, stearic acid, and hyaluronic acid.

24. The kit of claim 19, wherein the plasticizing material is a cellulose derivative selected from the group consisting of sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, and cellulose acetate butyrate.

25. The kit of claim 19, wherein the plasticizing material comprises hydroxypropylmethylcellulose.

26. The kit of claim 19, wherein the mixing solution comprises sterile water.

27. The kit of claim 19, wherein the mixing solution comprises a material selected from a group consisting of sodium chloride, phosphate buffered saline, potassium chloride, sodium sulfate, potassium sulfate, EDTA, ammonium sulfate, ammonium acetate, and sodium acetate.

28. The kit of claim 19, comprising: 100 parts of calcium sulfate hernihydrate; about 0.5 to about 5 parts of the plasticizing material; and about 10 to about 30 parts of the dernineralized bone.

29. The kit of claim 19, comprising;

100 parts of calcium sulfate hernihydrate; about 1 to about 3 parts of the plasticizing material; and about 15 to about 25 parts of the dernineralized bone.

30. The kit of claim 19, wherein said first mixture comprises surgical- grade calcium sulfate hernihydrate, calcium sulfate dihydrate, and hydroxypropylmethylcellulose, and said mixing solution comprising sterile water.

31. The kit of claim 30, comprising: 100 parts of calcium sulfate hernihydrate; about 0.5 to about 5 parts of calcium sulfate dihydrate; about 0.5 to about 5 parts of hydroxypropylmethylcellulose; and about 10 to about 30 parts of dernineralized bone.

32. The kit of claim 30, comprising: 100 parts of calcium sulfate hernihydrate; about 1 to about 4 parts of calcium sulfate dihydrate; about 1 to about 3 parts of hydroxypropylmethylcellulose; and about 15 to about 25 parts of dernineralized bone.